Laura Chico
Stock Analyst at Wedbush
(2.91)
# 1,609
Out of 4,944 analysts
215
Total ratings
35.95%
Success rate
0.57%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STOK Stoke Therapeutics | Maintains: Outperform | $16 → $22 | $15.44 | +42.49% | 7 | Aug 13, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $42 → $43 | $37.36 | +15.10% | 9 | Aug 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $32 | $17.81 | +79.67% | 12 | Aug 7, 2025 | |
| GOSS Gossamer Bio | Maintains: Outperform | $4 → $5 | $1.95 | +157.07% | 6 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $13 → $14 | $5.73 | +144.33% | 14 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $137 → $141 | $130.21 | +8.29% | 10 | Jul 31, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Neutral | $35 → $34 | $28.48 | +19.38% | 13 | Jul 14, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $17 | $13.80 | +23.19% | 1 | Jul 8, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $16 → $18 | $8.52 | +111.27% | 1 | Jun 30, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $17 → $15 | $3.84 | +290.63% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $128.09 | +1.49% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $134.00 | -9.70% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 | $21.32 | +26.64% | 7 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $6.24 | +172.44% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $7.22 | +135.46% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $3.18 | +25.79% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $14.28 | +110.08% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $22.19 | +17.17% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $48.95 | -42.79% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $13.75 | +212.73% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $22.90 | +87.77% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $0.67 | +347.76% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $19.91 | +80.86% | 6 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $6.91 | +305.21% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $24.64 | +17.69% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.17 | +925.64% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.66 | +91.26% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $18.81 | +123.29% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.50 | +2,092.74% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $5.09 | -1.79% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $57.66 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $3.02 | +65.56% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $13.83 | +973.75% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $9.48 | +7,494.94% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $61.06 | +358.60% | 1 | Apr 21, 2017 |
Stoke Therapeutics
Aug 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $15.44
Upside: +42.49%
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $37.36
Upside: +15.10%
Travere Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $17.81
Upside: +79.67%
Gossamer Bio
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.95
Upside: +157.07%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $5.73
Upside: +144.33%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $130.21
Upside: +8.29%
Ultragenyx Pharmaceutical
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $28.48
Upside: +19.38%
Maze Therapeutics
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $13.80
Upside: +23.19%
BioCryst Pharmaceuticals
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.52
Upside: +111.27%
Larimar Therapeutics
Jun 24, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $3.84
Upside: +290.63%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $128.09
Upside: +1.49%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $134.00
Upside: -9.70%
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $21.32
Upside: +26.64%
May 16, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $6.24
Upside: +172.44%
May 15, 2025
Reiterates: Outperform
Price Target: $17
Current: $7.22
Upside: +135.46%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $3.18
Upside: +25.79%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $14.28
Upside: +110.08%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $22.19
Upside: +17.17%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $48.95
Upside: -42.79%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $13.75
Upside: +212.73%
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $22.90
Upside: +87.77%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.67
Upside: +347.76%
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $19.91
Upside: +80.86%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $6.91
Upside: +305.21%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.64
Upside: +17.69%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.17
Upside: +925.64%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.66
Upside: +91.26%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $18.81
Upside: +123.29%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.50
Upside: +2,092.74%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $5.09
Upside: -1.79%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $57.66
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $3.02
Upside: +65.56%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $13.83
Upside: +973.75%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $9.48
Upside: +7,494.94%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $61.06
Upside: +358.60%